-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Type 2 diabetes (T2D) is associated with cardiovascular disease (CV) morbidity and mortality due to the combined effects of hyperglycemia and frequently associated obesity, dyslipidemia and hypertension
Background: Type 2 diabetes (T2D) is associated with cardiovascular disease (CV) morbidity and mortality due to the combined effects of hyperglycemia and frequently associated obesity, dyslipidemia and hypertension
Similar to SGLT2i, GLP-1RAs reduce cardiovascular disease (CVD) in patients with T2D, and the mode of action is not fully understood but may be multifactorial
OBJECTIVE: The aim of this study was to evaluate the mechanism by which SGLT2i dapagliflozin, GLP-1RA exenatide and dapagliflozin-exenatide lower blood pressure compared with placebo in obese and type 2 diabetic patients
METHODS: Sixty-six patients with type 2 diabetes were randomized to receive dapagliflozin 10 mg/d, exenatide 10 µg/d, dapagliflozin-exenatide or placebo for 16 weeks
Results: After 10 days of administration, dapagliflozin decreased blood pressure by 4.
Table 1 Changes in blood pressure and heart rate
Table 2 Cardiovascular function indicators
Table 2 Cardiovascular function indicatorsFigure 1 Linear mixed models were used to compare the effects of baseline-corrected treatment and placebo
Figure 1 Linear mixed models were used to compare the effects of baseline-corrected treatment and placebo
Conclusion: Plasma volume contraction induced by dapagliflozin may be involved in the initial decrease in SBP, and the decrease in SNS activity may be one of the reasons for the persistent decrease in SBP
Original source: van Ruiten CC, Smits MM, Kok MD, et al .
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial .
Cardiovasc Diabetol 2022 Apr 28;21(1) .
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial Leave a
comment here
